Background Cardiac hypertrophy is associated with elevated intracardiac angiotensin-converting enzyme activity, which may contribute to diastolic dysfunction. Methods and Results We infused enalaprilat (0.05 mg/min) for 15 minutes into the left coronary arteries of 20 adult patients with left ventricular (LV) hypertrophy due to aortic stenosis (mean aortic valve area, 0.7+/-0.2 cm(2)) and 10 patients with dilated cardiomyopathy (mean ejection fraction, 35+/-4%) and assessed (1) simultaneous changes in LV micromanometer pressure and dimensions, (2) LV regional wall motion analyzed by the area method, and (3) Doppler flow-velocity profiles. Systemic neurohormonal activation did not occur with the selective left coronary artery infusion; there...
Although angiotensin-converting enzyme inhibitors have been shown to affect left ventricular (LV) re...
Objective: Left ventricular (LV) hypertrophy is associated with increased diastolic chamber stiffnes...
BACKGROUND: Ranolazine is a new anti-anginal drug that acts via late sodium current inhibition, and ...
Background. In patients with heart failure, activation of the renin-angiotensin system is common and...
Background. In patients with heart failure, activation of the renin-angiotensin system is common an ...
OBJECTIVE: Angiotensin II has been suggested to be involved in the pathogenesis of diastolic dysfunc...
BACKGROUND. The aim of the present study was to analyze the changes in left ventricular diastolic fu...
Background. Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) man...
Background. The aim of the present study was to analyze the changes in left ventricular diastolic fu...
BACKGROUND: Angiotensin converting enzyme (ACE) inhibition exerts a favorable effect on the response...
Twenty patients with congestive heart failure caused by coronary heart disease (NYHA class III, IV) ...
Background. Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) man...
Systemic and coronary hemodynamic, metabolic and humoral effects of a new intravenous angiotensin-co...
We studied effects of enalaprilat and L-158,809, an angiotensin II type-1 receptor antagonist, on le...
Hypertensive left ventricular (LV) hypertrophy is an independent strong risk factor for cardiovascul...
Although angiotensin-converting enzyme inhibitors have been shown to affect left ventricular (LV) re...
Objective: Left ventricular (LV) hypertrophy is associated with increased diastolic chamber stiffnes...
BACKGROUND: Ranolazine is a new anti-anginal drug that acts via late sodium current inhibition, and ...
Background. In patients with heart failure, activation of the renin-angiotensin system is common and...
Background. In patients with heart failure, activation of the renin-angiotensin system is common an ...
OBJECTIVE: Angiotensin II has been suggested to be involved in the pathogenesis of diastolic dysfunc...
BACKGROUND. The aim of the present study was to analyze the changes in left ventricular diastolic fu...
Background. Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) man...
Background. The aim of the present study was to analyze the changes in left ventricular diastolic fu...
BACKGROUND: Angiotensin converting enzyme (ACE) inhibition exerts a favorable effect on the response...
Twenty patients with congestive heart failure caused by coronary heart disease (NYHA class III, IV) ...
Background. Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) man...
Systemic and coronary hemodynamic, metabolic and humoral effects of a new intravenous angiotensin-co...
We studied effects of enalaprilat and L-158,809, an angiotensin II type-1 receptor antagonist, on le...
Hypertensive left ventricular (LV) hypertrophy is an independent strong risk factor for cardiovascul...
Although angiotensin-converting enzyme inhibitors have been shown to affect left ventricular (LV) re...
Objective: Left ventricular (LV) hypertrophy is associated with increased diastolic chamber stiffnes...
BACKGROUND: Ranolazine is a new anti-anginal drug that acts via late sodium current inhibition, and ...